442 related articles for article (PubMed ID: 28071581)
1. Role of AQP4 Antibody Serostatus and its Prediction of Visual Outcome in Neuromyelitis Optica: A Systematic Review and Meta-Analysis.
Lin N; Liu Q; Wang X; Ma J; Li Y
Protein Pept Lett; 2017; 24(3):245-252. PubMed ID: 28071581
[TBL] [Abstract][Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
[TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
4. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.
Kitley J; Leite MI; Küker W; Quaghebeur G; George J; Waters P; Woodhall M; Vincent A; Palace J
JAMA Neurol; 2013 Nov; 70(11):1375-81. PubMed ID: 23999580
[TBL] [Abstract][Full Text] [Related]
5. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.
Jarius S; Wildemann B
Brain Pathol; 2013 Nov; 23(6):661-83. PubMed ID: 24118483
[TBL] [Abstract][Full Text] [Related]
6. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up.
Piccolo L; Woodhall M; Tackley G; Juryńczyk M; Kong Y; Domingos J; Gore R; Vincent A; Waters P; Leite MI; Palace J
J Neurol; 2016 Feb; 263(2):370-379. PubMed ID: 26668077
[TBL] [Abstract][Full Text] [Related]
7. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
8. The expanded spectrum of neuromyelitis optica: evidences for a new definition.
Lana-Peixoto MA; Callegaro D
Arq Neuropsiquiatr; 2012 Oct; 70(10):807-13. PubMed ID: 23060108
[TBL] [Abstract][Full Text] [Related]
9. Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis.
Li H; Wang Y; Xu Q; Zhang A; Zhou H; Zhao S; Kang H; Peng C; Cao S; Wei S
J Neurol; 2015 Oct; 262(10):2293-304. PubMed ID: 26162715
[TBL] [Abstract][Full Text] [Related]
10. Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.
Jiao Y; Fryer JP; Lennon VA; McKeon A; Jenkins SM; Smith CY; Quek AM; Weinshenker BG; Wingerchuk DM; Shuster EA; Lucchinetti CF; Pittock SJ
JAMA Neurol; 2014 Jan; 71(1):48-54. PubMed ID: 24248262
[TBL] [Abstract][Full Text] [Related]
11. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
[TBL] [Abstract][Full Text] [Related]
12. The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.
Jasiak-Zatonska M; Kalinowska-Lyszczarz A; Michalak S; Kozubski W
Int J Mol Sci; 2016 Mar; 17(3):273. PubMed ID: 26950113
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of clinical interest of anti-aquaporin-4 autoantibody followup in neuromyelitis optica.
Chanson JB; Alame M; Collongues N; Blanc F; Fleury M; Rudolf G; de Seze J; Vincent T
Clin Dev Immunol; 2013; 2013():146219. PubMed ID: 23710199
[TBL] [Abstract][Full Text] [Related]
14. Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India.
Ambika S; Balasubramanian M; Theresa L; Veeraputhiran A; Arjundas D
Int Ophthalmol; 2015 Dec; 35(6):801-6. PubMed ID: 25682013
[TBL] [Abstract][Full Text] [Related]
15. Aquaporin-4 antibody-negative neuromyelitis optica: distinct assay sensitivity-dependent entity.
Marignier R; Bernard-Valnet R; Giraudon P; Collongues N; Papeix C; Zéphir H; Cavillon G; Rogemond V; Casey R; Frangoulis B; De Sèze J; Vukusic S; Honnorat J; Confavreux C;
Neurology; 2013 Jun; 80(24):2194-200. PubMed ID: 23658379
[TBL] [Abstract][Full Text] [Related]
16. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
[TBL] [Abstract][Full Text] [Related]
17. Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography.
Peng CX; Li HY; Wang W; Wang JQ; Wang L; Xu QG; Cao SS; Zhou HF; Zhao S; Wei SH
Br J Ophthalmol; 2017 Aug; 101(8):1032-1037. PubMed ID: 28057643
[TBL] [Abstract][Full Text] [Related]
18. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Mader S; Gredler V; Schanda K; Rostasy K; Dujmovic I; Pfaller K; Lutterotti A; Jarius S; Di Pauli F; Kuenz B; Ehling R; Hegen H; Deisenhammer F; Aboul-Enein F; Storch MK; Koson P; Drulovic J; Kristoferitsch W; Berger T; Reindl M
J Neuroinflammation; 2011 Dec; 8():184. PubMed ID: 22204662
[TBL] [Abstract][Full Text] [Related]
19. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.
Jiao Y; Fryer JP; Lennon VA; Jenkins SM; Quek AM; Smith CY; McKeon A; Costanzi C; Iorio R; Weinshenker BG; Wingerchuk DM; Shuster EA; Lucchinetti CF; Pittock SJ
Neurology; 2013 Oct; 81(14):1197-204. PubMed ID: 23997151
[TBL] [Abstract][Full Text] [Related]
20. Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study.
Kovacs KT; Kalluri SR; Boza-Serrano A; Deierborg T; Csepany T; Simo M; Rokusz L; Miseta A; Alcaraz N; Czirjak L; Berki T; Molnar T; Hemmer B; Illes Z
Mult Scler; 2016 Aug; 22(9):1192-201. PubMed ID: 26514978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
